[NFS-02] Neuroscience Frontier Symposium 02

[NFS-02-4] αシヌクレインをターゲットにするパーキンソン病の治療戦略

池中 建介, Cesar Aguirre, 角田 渓太, 望月 秀樹 (大阪大学病院 神経内科)

As a clinical neurologist, Dr. Ikenaka has trained for 15 years and possesses a neurology specialist certification. His main clinical field is device-aided therapy for Parkinson's disease, especially that with LCIG. For clinical and biomarker research, he has been working to develop a biomarker to detect alpha-synuclein aggregates in the biosamples using the RT-QUIC system and trying to diagnose PD and MSA by monitoring the polymorphisms of the amplified aSyn aggregates from the patients. Also, as a neuroscientist, he has published more than 40 manuscripts targeting Parkinson's disease and ALS pathomechanisms. His recent interest is to uncover the mechanisms that impart the polymorphisms of the aSyn aggregates. We found that the environmental factor during the fibril formation affects the conformational states of aSyn monomer and leads to the different final products of the fibrils.